Yang Li1, Xu-Lin Xu1,2, Dan Zhao1, Lin-Na Pan3, Chun-Wei Huang1, Lian-Jun Guo1,2, Qing Lu1,2, Jian Wang4. 1. Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. The Key Laboratory for Drug Target Research and Pharmacodynamic Evaluation of Hubei Province, Wuhan, China. 3. Medical Department of Neurology, The Second Hospital of Nanchang, Nanchang, China. 4. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Abstract
AIMS: Brain ischemia activates astrocytes in a process known as astrogliosis. Although this process has beneficial effects, excessive astrogliosis can impair neuronal recovery. Polyinosinic-polycytidylic acid (Poly IC) has shown neuroprotection against cerebral ischemia-reperfusion injury, but whether it regulates reactive astrogliosis and glial scar formation is not clear. METHODS: We exposed cultured astrocytes to oxygen-glucose deprivation/reoxygenation (OGD/R) and used a rat middle cerebral artery occlusion (MCAO)/reperfusion model to investigate the effects of Poly IC. Astrocyte proliferation and proliferation-related molecules were evaluated by immunostaining and Western blotting. Neurological deficit scores, infarct volumes and neuroplasticity were evaluated in rats after transient MCAO. RESULTS: In vitro, Poly IC inhibited astrocyte proliferation, upregulated Toll-like receptor 3 (TLR3) expression, upregulated interferon-β, and downregulated interleukin-6 production. These changes were blocked by a neutralizing antibody against TLR3, suggesting that Poly IC function is TLR3-dependent. Moreover, in the MCAO model, Poly IC attenuated reactive astrogliosis, reduced brain infarction volume, and improved neurological function. In addition, Poly IC prevented MCAO-induced reductions in soma size, dendrite length, and number of dendritic bifurcations in cortical neurons of the infarct penumbra. CONCLUSIONS: By ameliorating astrogliosis-related damage, Poly IC is a potential therapeutic agent for attenuating neuronal damage and promoting recovery after brain ischemia.
AIMS: Brain ischemia activates astrocytes in a process known as astrogliosis. Although this process has beneficial effects, excessive astrogliosis can impair neuronal recovery. Polyinosinic-polycytidylic acid (Poly IC) has shown neuroprotection against cerebral ischemia-reperfusion injury, but whether it regulates reactive astrogliosis and glial scar formation is not clear. METHODS: We exposed cultured astrocytes to oxygen-glucose deprivation/reoxygenation (OGD/R) and used a ratmiddle cerebral artery occlusion (MCAO)/reperfusion model to investigate the effects of Poly IC. Astrocyte proliferation and proliferation-related molecules were evaluated by immunostaining and Western blotting. Neurological deficit scores, infarct volumes and neuroplasticity were evaluated in rats after transient MCAO. RESULTS: In vitro, Poly IC inhibited astrocyte proliferation, upregulated Toll-like receptor 3 (TLR3) expression, upregulated interferon-β, and downregulated interleukin-6 production. These changes were blocked by a neutralizing antibody against TLR3, suggesting that Poly IC function is TLR3-dependent. Moreover, in the MCAO model, Poly IC attenuated reactive astrogliosis, reduced brain infarction volume, and improved neurological function. In addition, Poly IC prevented MCAO-induced reductions in soma size, dendrite length, and number of dendritic bifurcations in cortical neurons of the infarct penumbra. CONCLUSIONS: By ameliorating astrogliosis-related damage, Poly IC is a potential therapeutic agent for attenuating neuronal damage and promoting recovery after brain ischemia.
Authors: Raffaella Gesuete; Amy E B Packard; Keri B Vartanian; Valerie K Conrad; Susan L Stevens; Frances R Bahjat; Tao Yang; Mary P Stenzel-Poore Journal: J Neurochem Date: 2012-11 Impact factor: 5.372
Authors: Fatemah Chehrehasa; Adrian C B Meedeniya; Patrick Dwyer; Greger Abrahamsen; Alan Mackay-Sim Journal: J Neurosci Methods Date: 2008-10-18 Impact factor: 2.390
Authors: Susan L Stevens; Thomas M P Ciesielski; Brenda J Marsh; Tao Yang; Delfina S Homen; Jo-Lynn Boule; Nikola S Lessov; Roger P Simon; Mary P Stenzel-Poore Journal: J Cereb Blood Flow Metab Date: 2008-01-09 Impact factor: 6.200
Authors: Dongxue Mao; Chloe M Reuter; Maura R Z Ruzhnikov; Anita E Beck; Emily G Farrow; Lisa T Emrick; Jill A Rosenfeld; Katherine M Mackenzie; Laurie Robak; Matthew T Wheeler; Lindsay C Burrage; Mahim Jain; Pengfei Liu; Daniel Calame; Sébastien Küry; Martin Sillesen; Klaus Schmitz-Abe; Davide Tonduti; Luigina Spaccini; Maria Iascone; Casie A Genetti; Mary K Koenig; Madeline Graf; Alyssa Tran; Mercedes Alejandro; Brendan H Lee; Isabelle Thiffault; Pankaj B Agrawal; Jonathan A Bernstein; Hugo J Bellen; Hsiao-Tuan Chao Journal: Am J Hum Genet Date: 2020-03-19 Impact factor: 11.025
Authors: Elizabeth A Mazzio; David Bauer; Patricia Mendonca; Equar Taka; Karam F A Soliman Journal: J Neuroimmunol Date: 2016-12-01 Impact factor: 3.478